These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease. Aponso PM, Faull RL, Connor B. Neuroscience; 2008 Feb 19; 151(4):1142-53. PubMed ID: 18201835 [Abstract] [Full Text] [Related]
4. Functional changes in the activity of cerebellum and frontostriatal regions during externally and internally timed movement in Parkinson's disease. Cerasa A, Hagberg GE, Peppe A, Bianciardi M, Gioia MC, Costa A, Castriota-Scanderbeg A, Caltagirone C, Sabatini U. Brain Res Bull; 2006 Dec 11; 71(1-3):259-69. PubMed ID: 17113955 [Abstract] [Full Text] [Related]
5. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C, Rodriguez M. Mov Disord; 2008 Dec 11; 23 Suppl 3():S548-59. PubMed ID: 18781672 [Abstract] [Full Text] [Related]
6. Manganese-enhanced MRI in a rat model of Parkinson's disease. Pelled G, Bergman H, Ben-Hur T, Goelman G. J Magn Reson Imaging; 2007 Oct 11; 26(4):863-70. PubMed ID: 17896372 [Abstract] [Full Text] [Related]
10. Spatial remapping of cortico-striatal connectivity in Parkinson's disease. Helmich RC, Derikx LC, Bakker M, Scheeringa R, Bloem BR, Toni I. Cereb Cortex; 2010 May 11; 20(5):1175-86. PubMed ID: 19710357 [Abstract] [Full Text] [Related]
11. Performing functional magnetic resonance imaging in patients with Parkinson's disease treated with deep brain stimulation. Arantes PR, Cardoso EF, Barreiros MA, Teixeira MJ, Gonçalves MR, Barbosa ER, Sukwinder SS, Leite CC, Amaro E. Mov Disord; 2006 Aug 11; 21(8):1154-62. PubMed ID: 16671094 [Abstract] [Full Text] [Related]
12. Basal ganglia neural responses during behaviorally effective deep brain stimulation of the subthalamic nucleus in rats performing a treadmill locomotion test. Shi LH, Luo F, Woodward DJ, Chang JY. Synapse; 2006 Jun 01; 59(7):445-57. PubMed ID: 16521122 [Abstract] [Full Text] [Related]
13. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease. Liu WG, Lu GQ, Li B, Chen SD. Parkinsonism Relat Disord; 2007 Mar 01; 13(2):77-88. PubMed ID: 16963309 [Abstract] [Full Text] [Related]
14. Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease. Steiner B, Winter C, Hosman K, Siebert E, Kempermann G, Petrus DS, Kupsch A. Exp Neurol; 2006 Jun 01; 199(2):291-300. PubMed ID: 16360152 [Abstract] [Full Text] [Related]
15. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM. Exp Neurol; 2001 Jun 01; 169(2):400-6. PubMed ID: 11358453 [Abstract] [Full Text] [Related]
17. Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism. Brown AR, Hu B, Antle MC, Teskey GC. Exp Neurol; 2009 Nov 01; 220(1):162-70. PubMed ID: 19703443 [Abstract] [Full Text] [Related]